Hospital
Alle-Kiski Medical Center
Alle-Kiski Medical Center was paid $6.09M by Medicaid between Jan 2019 and Dec 2024, across 178 billing codes. Its largest line is 99285, emergency room visit (most serious) — 30% of everything it billed.
33Billing provider infoALLE-KISKI MEDICAL CENTER
NATRONA HEIGHTS, PA 15065
NATRONA HEIGHTS, PA 15065
33aNPI1689679581assigned 06/16/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.09M
24GClaims188,533
24DCodes billed178
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#50 of 154
Median peer was paid$2.82M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 219 | $2K | |
| 2020 | 21,839 | $498K | |
| 2021 | 83,153 | $2.20M | |
| 2022 | 29,756 | $1.16M | |
| 2023 | 31,776 | $1.27M | |
| 2024incomplete | 21,790 | $962K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 30% | 11,395 | 10,960 | $1.82M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 9,000 | 8,788 | $1.16M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 7,271 | 7,087 | $1.04M |
| G0378 | Hospital observation service, per hour | 9.9% | 673 | 625 | $602K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.7% | 1,496 | 1,481 | $103K |
| 80053 | Comprehensive metabolic panel | 1.6% | 14,315 | 13,240 | $98K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 846 | 825 | $97K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 1,413 | 1,398 | $95K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 5,795 | 5,520 | $95K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,306 | 1,167 | $72K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 17,891 | 16,055 | $61K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,538 | 1,441 | $59K |
166 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 412 | $42K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,205 | $41K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 295 | $36K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,160 | $34K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 812 | $31K |
| 80050 | General health panel | <1% | 632 | $28K |
| 84484 | <1% | 3,949 | $24K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 234 | $23K |
| 80061 | Lipid panel | <1% | 1,589 | $23K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,017 | $23K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,239 | $20K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 339 | $19K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 314 | $18K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 452 | $17K |
| 93976 | <1% | 281 | $16K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,762 | $15K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,438 | $14K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 732 | $13K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 196 | $13K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 240 | $12K |
| 83880 | <1% | 612 | $11K | |
| 84703 | <1% | 1,527 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 244 | $9K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 115 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 613 | $9K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 59 | $8K |
| 93971 | <1% | 161 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 207 | $8K |
| 83735 | <1% | 1,482 | $8K | |
| 81001 | <1% | 4,495 | $7K | |
| 82805 | <1% | 313 | $7K | |
| 0100U | <1% | 190 | $7K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 634 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 975 | $7K |
| 76830 | Ultrasound, transvaginal | <1% | 161 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,020 | $7K |
| 83690 | <1% | 2,286 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 323 | $7K |
| 0002A | <1% | 123 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 321 | $6K |
| 0225U | <1% | 33 | $6K | |
| 84702 | <1% | 490 | $6K | |
| 84439 | <1% | 582 | $5K | |
| 0001A | <1% | 124 | $5K | |
| 80299 | <1% | 243 | $5K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 100 | $5K |
| 70498 | <1% | 60 | $5K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 120 | $5K |
| 70496 | <1% | 60 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 841 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,144 | $4K |
| 71250 | <1% | 83 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 263 | $4K |
| 84466 | <1% | 221 | $4K | |
| 12001 | <1% | 28 | $4K | |
| 85379 | <1% | 541 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 214 | $3K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 21 | $3K |
| 82607 | <1% | 247 | $3K | |
| 87040 | <1% | 246 | $3K | |
| 83605 | <1% | 656 | $3K | |
| 84999 | <1% | 1,278 | $3K | |
| 85610 | <1% | 1,128 | $3K | |
| 84145 | <1% | 268 | $3K | |
| 85027 | <1% | 551 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 87 | $3K |
| 82728 | <1% | 213 | $3K | |
| 96376 | <1% | 401 | $2K | |
| 73610 | <1% | 219 | $2K | |
| 84153 | <1% | 76 | $2K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 14 | $2K |
| 80076 | <1% | 239 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 295 | $2K |
| 83540 | <1% | 228 | $2K | |
| 85730 | <1% | 505 | $2K | |
| 82043 | <1% | 211 | $2K | |
| 87631 | <1% | 16 | $2K | |
| 82570 | <1% | 234 | $2K | |
| 73030 | <1% | 188 | $2K | |
| 73630 | <1% | 268 | $2K | |
| 72100 | <1% | 95 | $2K | |
| 87186 | <1% | 315 | $2K | |
| 86850 | <1% | 294 | $2K | |
| 73130 | <1% | 214 | $2K | |
| 81003 | <1% | 839 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 55 | $2K |
| 82550 | <1% | 378 | $2K | |
| 73502 | <1% | 117 | $1K | |
| 73562 | <1% | 135 | $1K | |
| 76642 | <1% | 39 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 38 | $1K |
| 80320 | <1% | 171 | $1K | |
| 86803 | <1% | 53 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 17 | $1K |
| 88342 | <1% | 54 | $1K | |
| 87481 | <1% | 27 | $1K | |
| 81025 | <1% | 462 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,851 | $1K |
| 86618 | <1% | 43 | $995.91 | |
| 93017 | <1% | 28 | $877.69 | |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $824.18 |
| 86140 | <1% | 319 | $819.23 | |
| 86900 | <1% | 301 | $796.93 | |
| 86901 | <1% | 299 | $787.84 | |
| 87081 | <1% | 194 | $778.67 | |
| 87077 | <1% | 237 | $773.48 | |
| 84100 | <1% | 153 | $734.29 | |
| 82962 | <1% | 584 | $713.12 | |
| 85652 | <1% | 281 | $701.68 | |
| 96367 | <1% | 58 | $698.04 | |
| 73110 | <1% | 92 | $662.24 | |
| 82553 | <1% | 183 | $660.53 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 35 | $651.37 |
| 70486 | <1% | 14 | $591.72 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,774 | $482.67 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,398 | $479.65 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 13 | $475.65 |
| J3490 | Unclassified drugs | <1% | 1,944 | $432.77 |
| 82565 | <1% | 65 | $419.59 | |
| 80349 | <1% | 49 | $399.40 | |
| 76870 | <1% | 15 | $355.96 | |
| 82746 | <1% | 33 | $340.13 | |
| 87486 | <1% | 21 | $310.60 | |
| 84550 | <1% | 46 | $274.58 | |
| 80329 | <1% | 61 | $264.21 | |
| 74018 | <1% | 18 | $234.02 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,089 | $225.64 |
| 87205 | <1% | 57 | $223.36 | |
| 90715 | <1% | 82 | $213.32 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,853 | $191.13 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 65 | $173.05 |
| 87070 | <1% | 27 | $171.58 | |
| 73560 | <1% | 18 | $161.78 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 528 | $153.87 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 195 | $142.84 |
| 87147 | <1% | 58 | $135.97 | |
| 84436 | <1% | 12 | $134.08 | |
| 87088 | <1% | 26 | $120.48 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,592 | $114.99 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $110.41 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 44 | $106.35 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,583 | $101.62 |
| 73590 | <1% | 14 | $99.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 336 | $74.23 |
| 82248 | <1% | 13 | $71.43 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,017 | $70.92 |
| 87581 | <1% | 18 | $62.04 | |
| 82947 | <1% | 13 | $55.86 | |
| 97162 | <1% | 14 | $38.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 19 | $35.54 |
| J1815 | Injection, insulin, per 5 units | <1% | 139 | $33.46 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 934 | $30.66 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 147 | $29.11 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 526 | $24.58 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 45 | $16.71 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 72 | $12.79 |
| A9270 | Non-covered item or service | <1% | 17,829 | $9.09 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 42 | $6.50 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 76 | $5.24 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 19 | $4.59 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 16 | $4.23 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 118 | $0.47 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,571 | $0.10 |
| J7999 | Compounded drug, not otherwise classified | 0% | 29 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 14 | $0.00 |
| 90686 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRIES, RICK (VP, FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Jefferson Regional Medical Center | Clairton, PA | $12.73M |
| West Penn Allegheny Health System INC | Pittsburgh, PA | $12.69M |
| West Penn Allegheny Health System INC. | Pittsburgh, PA | $10.81M |
| West Penn Allegheny Health System INC. | Monroeville, PA | $8.24M |
| Canonsburg General Hospital | Canonsburg, PA | $2.97M |
| Grove City Medical Center | Grove City, PA | $2.17M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.